Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.
about
Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor traffickingDifferential structural plasticity of corticostriatal and thalamostriatal axo-spinous synapses in MPTP-treated Parkinsonian monkeys.Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signalingNew Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders.The thorny problem of dyskinesias: dendritic spines, synaptic plasticity, and striatal dysfunctionImpact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian ratsAstrocytosis in parkinsonism: considering tripartite striatal synapses in physiopathology?Neuroglial plasticity at striatal glutamatergic synapses in Parkinson's diseaseL-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission.Zooming in on the small: the plasticity of striatal dendritic spines in L-DOPA-induced dyskinesia.The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's diseaseRole of vitamin d in Parkinson's disease.Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapsesStriatal shape in Parkinson's disease.Differential striatal spine pathology in Parkinson's disease and cocaine addiction: a key role of dopamine?L-type calcium channels and psychiatric disorders: A brief review.Impact of gating modulation in CaV1.3 L-type calcium channels.The changing landscape of voltage-gated calcium channels in neurovascular disorders and in neurodegenerative diseasesAdvances in non-dopaminergic treatments for Parkinson's diseaseRegulation of Postsynaptic Stability by the L-type Calcium Channel CaV1.3 and its Interaction with PDZ ProteinsL-type Ca2+ channels in heart and brainChanges in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia.Loss and remodeling of striatal dendritic spines in Parkinson's disease: from homeostasis to maladaptive plasticity?Effect of chronic L-dopa or melatonin treatments after dopamine deafferentation in rats: dyskinesia, motor performance, and cytological analysis.Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteins.Methods for treating neurological conditions (WO2011159945).Levodopa treatment and dendritic spine pathology.Proteomic analysis of striatum from MPTP-treated marmosets (Callithrix jacchus) with L-DOPA-induced dyskinesia of differing severity.The role of calcium channel blockers and resveratrol in the prevention of paraquat-induced parkinsonism in Drosophila melanogaster: a locomotor analysis.Therapy for dyskinesias in Parkinson’s disease patients
P2860
Q26768220-6AA90256-213A-47B1-8115-1E3320AC2B5FQ27324174-5E33BB87-886B-414C-B47C-4604F3974018Q28582674-A3D38D43-D269-472F-9249-469D835777ACQ30498354-EE2A023C-5BF9-467F-AE06-58080344C710Q33428476-CD428B0D-81BE-4C7E-8B2C-A2FA3605ECADQ33783000-BB9B4CC0-0838-45B8-AF30-AF22C54BEA42Q33996876-81A3C4A6-CDAF-4091-B165-50B6F56FC18AQ34131256-4E7F7D5E-7F9E-48B2-A780-F1861606AAE9Q34238909-CC58BE07-E865-48BA-9DA0-38E856DFBA0CQ35176103-4F661ECF-A987-4AAC-8B96-BC8240947466Q35424424-EBB285AD-40A6-451D-AB0E-BEAA4E1BAA04Q35574934-518009C4-E297-4531-8773-E5BA5251A28CQ35607214-434A2D49-3734-48F3-B05B-632747AA649EQ35949729-3ECB8252-C84F-4F50-AE73-C10A39CD1FC7Q37048087-6F640290-DEE8-4D4C-9247-975E03647910Q37093252-2A76558A-531C-4D3C-930D-7586779E1872Q37185190-EA26FA7D-B8E7-4134-A134-027571383986Q37795701-69EF7E3D-1B9D-4DD5-B379-2438C281C123Q37819813-691B6B21-BE60-4683-A4B5-0CDFF5A5DAB8Q38157892-01A87ADF-7F9D-4089-A3DA-AEBB127C2534Q38218083-45F84D0B-7264-45F1-BC6D-5F09D1A237A5Q38475692-B739414F-8895-4EDD-AE6E-F85D2C37A12DQ38543572-4E0228BB-5270-4AE8-9B31-EF775066AB3FQ38719357-06D00732-174F-4A69-A696-24379D4CD99DQ38766091-C0977237-70FC-43FC-A7BB-3890537CD2BDQ42127267-F0DF0E41-1AC4-4DBF-A954-5D0DE2E8DCBBQ44936401-21511B7E-8C33-47F8-8F35-FBE49F9882C1Q45340134-FBF7BA2F-5026-44C4-A23A-4BE2C8FDB5E7Q48113066-0BDB3628-D867-46D6-9AE6-AB31A564CFDCQ48917568-EF69B245-235B-45B6-A9DC-6E1426003B07Q52719394-B083563A-4D3C-4CD8-87E8-5D79692DD2A7Q57518128-B8C4406D-8E33-4B8E-84DF-FEDD8786E8C7
P2860
Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Antagonizing L-type Ca2+ chann ...... nylalanine-induced dyskinesia.
@en
Antagonizing L-type Ca2+ chann ...... nylalanine-induced dyskinesia.
@nl
type
label
Antagonizing L-type Ca2+ chann ...... nylalanine-induced dyskinesia.
@en
Antagonizing L-type Ca2+ chann ...... nylalanine-induced dyskinesia.
@nl
prefLabel
Antagonizing L-type Ca2+ chann ...... nylalanine-induced dyskinesia.
@en
Antagonizing L-type Ca2+ chann ...... nylalanine-induced dyskinesia.
@nl
P2093
P50
P1476
Antagonizing L-type Ca2+ chann ...... enylalanine-induced dyskinesia
@en
P2093
Amandine Berthet
Bastian Hengerer
Bertrand Bloch
Carina Ittrich
D James Surmeier
Incarnation Aubert
M Angela Cenci
Stefan Schuster
P304
P356
10.1016/J.BIOPSYCH.2008.09.008
P407
P577
2008-10-23T00:00:00Z